Data Show Galvus Better Tolerated by Patients with type 2 Diabetes, with no Weight Gain, a Favorable Cardiovascular Profile and Equal Efficacy Compared to Widely-used TZDs
• GALIANT* study in more than 2,400 patients shows Galvus as effective as commonly prescribed TZD drugs when added to metformin1
• New pooled data show Galvus is associated with lower overall incidence of cardiovascular and cerebrovascular events, such as heart attacks and strokes, than placebo2 and confirm good tolerability in patients with mild-to-moderate
renal impairment3
• Patients tolerated Galvus better than TZDs and did not gain weight – a common side effect of other type 2 diabetes medicines1
• Galvus demonstrates strong efficacy in broad patient population with over 14,000 patients treated in clinical program to date
BASEL, Switzerland, Sept. 9, 2008 — New data show Galvus® (vildagliptin), an oral treatment for type 2 diabetes, is better tolerated and as effective as commonly prescribed anti-diabetic oral medicines, called thiazolidinediones (TZDs), when added to metformin1. Patients treated with Galvus did not gain weight, a common side effect of other type 2 diabetes medicines, regardless of their race, body mass index or age1.
The results come from GALIANT, a study involving more than 2,400 patients treated by primary care physicians1. The GALIANT data were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Rome, Italy.
Type 2 diabetes is estimated to affect more than 53 million people in Europe4. Controlling blood sugar is difficult and up to 65% of diabetes patients fail to meet their recommended blood sugar levels5. When left untreated or not kept under control, type 2 diabetes can lead to heart and kidney disease, blindness and vascular or neurological problems6.
Other data presented at EASD demonstrated the favorable cardiovascular safety profile of Galvus2 and confirmed its tolerability in patients with mild-to-moderate renal impairment3.
“The GALIANT study reflects the true nature and diversity of the type 2 diabetes patient population,” said Richard Pratley, MD, Director of the Diabetes & Metabolism Translational Medicine Unit at the University of Vermont College of Medicine, USA.
“The use of early combination therapy is becoming increasingly important to help patients achieve their recommended blood sugar levels. This study shows that Galvus is effective and well tolerated in this diverse group of patients in a primary care setting.”
Galvus 100 mg once-daily was used in the GALIANT study. Galvus received European Commission approval for 50 mg twice-daily in combination with the most frequently prescribed oral anti-diabetes medicines, metformin or a TZD, and Galvus 50 mg once-daily
in combination with sulphonylureas (SUs). The GALIANT study was amended to a smaller population from the initially planned patient study to ensure an earlier assessment of important comparative efficacy and safety of Galvus compared to TZDs.
The 12-week GALIANT study showed that the efficacy of Galvus 100 mg once-daily was non-inferior to that of TZDs (-0.68% vs. -0.57% HbA1c respectively, p=0.001) in patients with type 2 diabetes whose blood sugar levels were inadequately controlled (HbA1c >7%) with metformin alone1. HbA1c is the standard measure of blood sugar.
The study also showed that patients treated with Galvus lost weight, whereas those on TZDs put on weight (-0.58 kg ±0.09 kg vs. +0.33 kg ±0.11 kg respectively)1. This is a key benefit as many patients with type 2 diabetes struggle to keep their weight under control. “The GALIANT study demonstrates that Galvus is an effective treatment option without the associated weight gain seen with commonly prescribed drugs for patients who are currently on metformin but not reaching their recommended blood sugar levels,” said Trevor Mundel, MD, Head of Global Development Functions at Novartis Pharma AG. Other data presented at EASD include a pooled analysis from approximately 6,000 patients demonstrating that Galvus has a favorable cardiovascular profile, with a lower
overall incidence of cardiovascular and cerebrovascular events, such as heart attacks and strokes, than placebo2. Concerns have recently been raised over the cardiovascular safety profile of older oral anti-diabetic medicines, including TZDs and SUs7.
Separately, an analysis of pooled data from over 1,400 patients reinforced that Galvus is well tolerated in type 2 diabetes patients with mild-to-moderate renal impairment3. Decreased renal function is more common in patients with type 2 diabetes8, with the
prevalence of kidney disease ranging from 20-40%9. The analysis also confirmed there were no adverse changes in renal function following long-term treatment with Galvus3. Similar efficacy was achieved in patients with mild renal impairment and those with
normal renal function3. Galvus is currently not recommended for patients with moderate or severe renal impairment in Europe.
Additionally, at EASD Novartis celebrated the 10th annual Novartis Prize in Diabetes, an award created to stimulate innovation in diabetes clinical research and to recognize outstanding individuals who have dedicated themselves to improving the lives of people
with diabetes. For more information about the Novartis Prize in Diabetes, please visit www.diabetesaward.novartis.com.
Galvus and Eucreas, a single-pill combination of Galvus and metformin, are approved as oral treatments for type 2 diabetes patients in all 27 countries of the European Union as well as in Norway and Iceland. Galvus is currently available in 18 countries, namely Italy,
the UK, Germany, Netherlands, Denmark, Norway, Greece, Malta, Poland, Ireland, Spain, Switzerland, Mexico, Brazil, Argentina, the Philippines, Singapore and India, and is approved in 51 countries. Eucreas is available in 10 countries.
In the US, some small clinical studies have started amid discussions with the FDA on overall steps needed for approval after an "approvable letter" in February 2007. However, resubmission for US approval is not planned at this time.
Galvus works through a novel mechanism of action by targeting the dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes.
Islet dysfunction, along with insulin resistance, is a contributory factor in type 2 diabetes. In combination with the most widely prescribed type 2 diabetes medicines, Galvus delivers significant blood sugar reductions with a good tolerability profile in a broad range of patients10,11. Galvus demonstrates strong efficacy in a broad patient population with over 14,000 patients treated in the clinical program to date.
The overall incidence of side effects has been shown to be similar to placebo with the most frequent being stuffy nose, headaches, dizziness and upper respiratory tract infection10. Galvus is not recommended for patients with liver impairment, and liver monitoring should be conducted at the start of treatment, every three months for the first year, and periodically thereafter. Galvus should not be used in patients with type 1 diabetes.
Novartis is focused on improving the lives of the hundreds of millions of people with cardiovascular and metabolic diseases. As a global leader in cardiovascular and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat high blood pressure and diabetes – both major public health issues. The portfolio includes the world's most-prescribed angiotensin receptor blocker, the first and only approved direct renin inhibitor, a single pill combining two leading high blood pressure
medicines, and a novel DPP-4 inhibitor. Novartis is dedicated to helping physicians and patients through effective medicines, programs and an ongoing commitment to research.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as “becoming”, “approvable”, “planned”, “commitment”, or similar expressions, or by express or implied discussions regarding potential future approvals to
sell Galvus in additional markets, including in the US, or regarding potential future revenues from Galvus. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties
and other factors that may cause actual results with Galvus to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Galvus will be approved for sale in any additional market. Nor can there be any guarantee that Galvus will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding Galvus could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the affect that the foregoing factors could have on the values attributed to the Group’s assets and liabilities as recorded in the Group’s balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group’s continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
References
1 Braceras R, et al. “Vildagliptin is as Effective as TZDs in Metformin Failures: Results of GALIANT - A
Primary Care Diabetes Study.” Presented at EASD 6-11 September 2008 (Abstract P-914).
2 Kothny W, et al. “Cardiovascular Safety Profile of Vildagliptin, a New DPP-4 Inhibitor for the Treatment
of Type 2 Diabetes.” Presented at EASD 6-11 September 2008 (Poster P-915).
3 Thuren T, et al. “Vildagliptin is Safe and Well Tolerated in Patients with Mild or Moderate Renal
Impairment.” Presented at EASD 6-11 September 2008 (Oral Presentation OP-74).
4 International Diabetes Federation. ‘Diabetes Atlas.’ 2006: Third edition.
5 Saydah S, et al. Race and ethnic differences in glycemic control among adults with diagnosed diabetes in
the United States. Ethn Dis 2007; 17:529-535.
6 International Diabetes Federation. ‘Complications of Diabetes’ 2008:
http://www.idf.org/home/index.cfm?node=13.
7 Dluhy RG, et al. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. The New England
Journal of Medicine 2008; 358 (24): 2630-2633.
8 Coresh J. Prevalence of Chronic Kidney Disease and Decreased Kidney Function in the Adult US
Population: Third National Health and Nutrition Examination Survey. American Journal of Kidney
Diseases 2003;41;1:1-12.
9 Young BA, et al. Diabetes and Renal Disease in Veterans. Diabetes Care 27 (suppl 2): B45-49.
10 Novartis: Data on File.
11 Garber A, et al. Effects of Vildagliptin on Glucose Control in Patients with Type 2 Diabetes Inadequately
Controlled with a Sulphonylurea. Diabetes, Obesity and Metabolism 2008; 10:1326-1463.
# # #
Novartis Media Relations
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com
Navjot Rai
Novartis Pharma Communications
+41 61 324 6498 (direct)
+41 79 777 6400 (mobile)
navjot.rai@novartis.com
e-mail: media.relations@novartis.com
Novartis Investor Relations
Central phone: +41 61 324 7944
Ruth Metzler-Arnold +41 61 324 9980 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Jarvis +1 212 830 2433
John Gilardi +41 61 324 3018 Jill Pozarek +1 212 830 2445
Thomas Hungerbuehler +41 61 324 8425 Edwin Valeriano +1 212 830 2456
Isabella Zinck +41 61 324 7188
e-mail: investor.relations@novartis.com e-mail: investor.relations@novartis.com
Posted: September 2008
